SEC Form 4: Flynn James E sold $5,332 worth of shares (13,786 units at $0.39)

$ONCR
Medicinal Chemicals and Botanical Products
Health Care
Get the next $ONCR alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Flynn James E

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oncorus, Inc. [ ONCR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) X Other (specify below)
*Possible Member of 10% Group
3. Date of Earliest Transaction (Month/Day/Year)
12/13/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/13/2022 S 934 D $0.41(1) 1,400,971 I Through Deerfield Healthcare Innovations Fund, L.P.(4)(5)
Common Stock 12/13/2022 S 933 D $0.41(1) 1,400,972 I Through Deerfield Private Design Fund III, L.P.(4)(5)
Common Stock 12/13/2022 S 230 D $0.41(1) 344,937 I Through Deerfield Partners, L.P.(4)(5)
Common Stock 12/14/2022 S 3,828 D $0.38(2) 1,397,143 I Through Deerfield Healthcare Innovations Fund, L.P.(4)(5)
Common Stock 12/14/2022 S 3,829 D $0.38(2) 1,397,143 I Through Deerfield Private Design Fund III, L.P.(4)(5)
Common Stock 12/14/2022 S 943 D $0.38(2) 343,994 I Through Deerfield Partners, L.P.(4)(5)
Common Stock 12/15/2022 S 1,375 D $0.39(3) 1,395,768 I Through Deerfield Healthcare Innovations Fund, L.P.(4)(5)
Common Stock 12/15/2022 S 1,375 D $0.39(3) 1,395,768 I Through Deerfield Private Design Fund III, L.P.(4)(5)
Common Stock 12/15/2022 S 339 D $0.39(3) 343,655 I Through Deerfield Partners, L.P.(4)(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Flynn James E

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Deerfield Mgmt HIF, L.P.

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
1. Name and Address of Reporting Person*
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Deerfield Healthcare Innovations Fund, L.P.

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Deerfield Mgmt L.P.

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Deerfield Mgmt III, L.P.

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Deerfield Private Design Fund III, L.P.

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
1. Name and Address of Reporting Person*
DEERFIELD PARTNERS, L.P.

(Last) (First) (Middle)
345 PARK AVENUE SOUTH
12TH FLOOR

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
Explanation of Responses:
1. The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.40 to $0.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1-3 of this Form 4.
2. The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.37 to $0.38, inclusive.
3. The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.39 to $0.41, inclusive.
4. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund III and Deerfield Partners, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.
5. In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Remarks:
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.
/s/ Jonathan Isler, Attorney-in-Fact 12/15/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ONCR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ONCR

DatePrice TargetRatingAnalyst
More analyst ratings

$ONCR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Oncorus Announces Workforce Reduction Plan

    ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company's board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus' workforce, which is expected to be completed by August 2023. Theodore (Ted) Ashburn, M.D., Ph.D. (Chief Executive Officer), Stephen W. Harbin (C

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

    IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

    Research collaboration leverages Oncorus' proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong's mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care

$ONCR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ONCR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ONCR
SEC Filings

See more

$ONCR
Leadership Updates

Live Leadership Updates

See more
  • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

    IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Appoints Douglas Fambrough to Board of Directors

    -Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

    CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care

$ONCR
Financials

Live finance-specific insights

See more
  • Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

    Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

    Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021

    ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care

$ONCR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more